Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system’s efficacy and safety in treating Alzheimer's disease. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback